Therapeutic Antibodies

#CatalYm #Financing #Monoclonal antibodies #Oncology #Phase II trial

CatalYm raises $150m for cancer therapy visugromab

CatalYm has completed a $150 million Series D financing to support the Phase II development of its cancer therapy visugromab. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, Brandon… Read More

#Business & Investment #Cancer Research #News

Monoclonal antibody
#Autoimmune disease #Janssen #Monoclonal antibodies #Neurology #Phase III trial

Janssen reports positive data for myasthenia gravis treatment

Janssen-Cilag has reported positive results from its Phase III Vivacity-MG3 study assessing its nipocalimab therapy for the treatment of patients with generalised myasthenia gravis (gMG). The Johnson & Johnson company showcased the data in a presentation at the European Academy of Neurology (EAN) 2024 Congress and… Read More

#News

Enterovirus
#Clinical trial #Monoclonal antibodies #National Institutes of Health (NIH) #Virology

Trial to test monoclonal antibody for virus of growing concern

The National Institutes of Health (NIH) is sponsoring a clinical trial to evaluate the safety of an investigational monoclonal antibody to treat enterovirus D68 (EV-D68), which can cause severe respiratory and neurological diseases such as acute flaccid myelitis (AFM). AFM has emerged in the United States… Read More

#News #Trending News

Immune thrombocytopenia test
#Events #ITP #Monoclonal antibodies #Phase II trial #Takeda

Favourable results for mAb in bleeding disorder shared at ISTH

Takeda has shared positive results from its Phase IIb study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterised by the accelerated destruction of platelets in blood, resulting… Read More

#News

Woman with a nose bleed
#Bispecific Antibodies #Events #Haemophilia #Novo Nordisk #Phase III trial

Bispecific antibody successfully reduced bleeds in haemophilia A

Novo Nordisk has announced results from the Phase III FRONTIER2 trial of 254 adults and adolescents aged 12 years and over with haemophilia A, with and without inhibitors. The trial assessed both once-weekly and once-monthly prophylactic treatment with the investigational treatment Mim8. The data… Read More

#News

Therapeutic antibodies
#Antibody drug conjugate (ADC) #Bispecific Antibodies #Drug discovery #eBook #Therapeutic Antibodies

eBook: The impact of therapeutic antibody discovery

A new eBook, sponsored by Sino Biological, is now available for download entitled ‘The impact of therapeutic antibody discovery’. The first monoclonal antibody (mAb), Orthoclone, was approved in 1986 to help prevent rejection in organ transplantation. Since then, the US Food and Drug… Read More

#News

#Therapeutic Antibodies

eBook: The impact of therapeutic antibody discovery

This eBook sponsored by Sino Biological explores the challenges and opportunities in the therapeutic antibody market, the range of applications for these therapies and the move towards more targeted and effective next-generation antibody treatments. Download this exclusive eBook to learn more about:   How artificial intelligence and machine learning are… Read More

#DDW eBooks

Antibodies attacking virus
#Antibodies #Chiba University #Covid-19 #Immune system

Could auto-antibodies be linked to severe Covid-19?

Researchers have revealed that auto-antibodies block interferon signalling, contributing to severe Covid-19 by impairing the patient’s immune response. Scientists have found that some people who suffered from Covid-19 had auto-antibodies targeting their own type 1 interferons, which are important immune signalling proteins. Factors such… Read More

#News #Trending News

Blood cancer
#Antibodies #Blood cancer #CAR-T #Cell therapy #Clinical trials #Events #Haematology

EHA2024: Industry shares latest drug research in blood cancers

A number of key findings in haematological malignancies were revealed at this year’s European Hematology Association (EHA) Congress, which was held in Madrid, Spain 13-16 June. Ibrutinib and talquetamab, Johnson & Johnson Johnson & Johnson shared clinical trial results for its drug candidates Talvey (talquetamab) and… Read More

#Cancer Research #News #Trending News

Human cells
#Cytomos #Immunotherapy #iPSC #Monoclonal antibodies #Single-cell analysis

Cytomos launches new benchtop cell analyser

TechBio Cytomos has launched a new benchtop cell analyser called Celledonia, which uses the company’s AuraCyt platform. Celledonia has been designed to provide cell-specific insights for modalities including monoclonal antibodies (mAbs), T cell immunotherapies, and induced pluripotent stem cells (iPSCs). The new technology could… Read More

#News

Bispecific antibodies
#AbbVie #ASCO #Bispecific Antibodies #Follicular lymphoma #Genmab #Haematology #Oncology

95% response to bispecific antibody in follicular lymphoma

Previously untreated follicular lymphoma (FL) patients who received epcoritamab with rituximab-lenalidomide (R2) had a 95% overall response rate (ORR), according to preliminary trial data. The results of two ongoing Phase I/II clinical trials evaluating cancer immunotherapy epcoritamab, a T-cell engaging bispecific antibody, were shared at… Read More

#Cancer Research #News #Trending News

Antibody drug conjugate
#Antibodies #Antibody drug conjugate (ADC) #Cancer research #Funding #Pheon Therapeutics #Solid tumours

$120m raised to develop differentiated ADC pipeline 

Pheon Therapeutics has completed a $120m Series B financing to fund the development of its pipeline of next generation ADCs for a wide range of hard-to-treat cancers.  The new financing will be used to further advance Pheon’s differentiated ADC pipeline through clinical proof of concept. The first three assets are… Read More

#Business & Investment #Cancer Research #News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The ongoing innovation and development in the drug discovery sector relies on a number… Read More

#News

Monoclonal antibody
#Bioprocessing #Drug discovery #Monoclonal antibodies #Sustainability

How single-use technologies can improve antibodies production  

DDW Editor Reece Armstrong speaks to David Chau, Global Bioprocess Application Specialist, Purification and Filtration Business, Solventum, formerly 3M Health Care, about challenges in producing monoclonal antibodies (mAbs) and how single-use technologies can simplify processes.   RA: What are some of the current limitations for producing mAbs? DC: For the… Read More

#Exclusive Content